Physicians' Academy for Cardiovascular Education

Asian Interchange on Diabetes

July 30, 2016

Asian Interchange on Diabetes


3 0 – 3 1 J U LY, 2016, B A N G KO K , T H A I L A N D

 

Innovation in T2DM: How will novel interventions impact clinical care?


This Asian Interchange on Diabetes is in collaboration with PACE-CME (Physicians’ Academy for Cardiovascular Education) and ACROSS T2D (Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes).

The mission of PACE-CME is to improve the cardiovascular health of patients by providing an international forum for the review, exchange and assimilation of new important data underlying cardiovascular disease and diabetes and accelerate the translation of this information into clinical practice.

During this Asian Interchange on Diabetes a balanced review was provided on how novel developments might impact your clinical practice in managing your patients with T2DM.
 

See here the educational agenda and programme book

AID 2016 programbook.pdf (1,2MB)AID 2016 programbook.pdf (1,2MB)


View and download teaching slides  

 

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Presentation prepared and held by Richard E. Pratley, MD - Florida Hospital Diabetes Institute, Orlando, Fl, USA, held on July 30-31, 2016 in Bangkok, Thailand.
 

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Presentation prepared and held by David Fitchett, MD - University of Toronto, Canada on July 30-31, 2016 in Bangkok, Thailand.
 

Understanding Diabetes Kidney Disease: What are the best options for clinical management?

Presentation prepared and held by Per-Hendrik Groop, MD - University of Helsinki, Finland. on July 30-31, 2016 in Bangkok, Thailand.
 

Diabetes in Asia: What is different from the west?

Presentation prepared and held by Chaicharn Deerochanawong , MD, Rajavithi Hospital College of Medicine, Bangkok, Thailand on July 30-31, 2016 in Bangkok, Thailand.
 

Update on DPP4 inhibition in T2DM: Implications from recent and ongoing trials

Presentation prepared and held by Richard E. Pratley, MD - Florida Hospital Diabetes Institute, Orlando, Fl, USA on July 30-31, 2016 in Bangkok, Thailand


Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME

Presentation prepared and held by David Fitchett, MD - University of Toronto, Canada on July 30-31, 2016 in Bangkok, Thailand.


Watch short 3 minute video recordings with the faculty

 

SGLT2 inhibition in diabetic kidney disease

Prof. Per-Henrik Groop, MD - University of Helsinki, Finland

 

A changing treatment paradigm in diabetes

Prof. Richard E. Pratley, MD - Florida Hospital Diabetes Institute, Orlando, FL, USA

 

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Prof. Per-Henrik Groop, MD - University of Helsinki, Finland

 

Funding

The program was supported by an educational grant from Boehringer Ingelheim (Singapore)